Premium
Topiramate and physiologic measures of nerve function in polyneuropathy
Author(s) -
Freeman R.,
McIntosh K. A.,
Vijapurkar U.,
Thienel U.
Publication year - 2007
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2006.00789.x
Subject(s) - topiramate , placebo , medicine , anesthesia , polyneuropathy , nerve conduction velocity , sural nerve , nerve conduction study , nerve conduction , surgery , epilepsy , pathology , alternative medicine , psychiatry
Objective – To evaluate topiramate treatment on nerve function using electrophysiologic methods and a non‐inferiority clinical trial design. Methods – A double‐blind, multicenter, placebo‐controlled trial was conducted in patients with painful diabetic polyneuropathy ( n = 67). Change in peroneal motor nerve conduction velocity (NCV) was the primary outcome. NCVs of sural sensory and ulnar nerves, and amplitude and latency changes were measured secondarily. Peripheral nerve function was also evaluated in a patient subgroup reporting treatment‐emergent paresthesias. Result – Least squares mean decrease in NCV was greater for placebo (−0.2 m/s) than for topiramate treatment (−0.1 m/s) (95% CI: −1.30, 1.42). Secondary measures showed no decrease in nerve function for topiramate‐treated patients. Neurophysiologic measures were similar in patients with and without paresthesias. The most common adverse events with topiramate were paresthesias, anorexia, weight decrease, and taste perversion. Conclusion – This nerve conduction study found no evidence that topiramate is associated with deterioration of nerve function.